Identification

Name
Etomidate
Accession Number
DB00292  (APRD00965)
Type
Small Molecule
Groups
Approved
Description

Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic. [PubChem]

Structure
Thumb
Synonyms
  • (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate
  • (+)-ethyl 1-(α-methylbenzyl)imidazole-5-carboxylate
  • (+)-etomidate
  • (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester
  • (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester
  • 3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester
  • Etomidate
  • Etomidato
  • Etomidatum
  • R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AmidateInjection, solution2 mg/mLIntravenousGeneral Injectables & Vaccines2010-03-102017-09-29Us
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-072017-04-19Us
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-07Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-07Not applicableUs
AmidateInjection, solution2 mg/mLIntravenousHospira, Inc.1982-09-072017-04-19Us
AmidateInjection, solution2 mg/mLIntravenousGeneral Injectables & Vaccines2010-08-01Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EtomidateInjection2 mg/mLIntravenousPfizer Laboratories Div Pfizer Inc.2012-02-03Not applicableUs
EtomidateInjection2 mg/mLIntravenousHeritage2012-09-13Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousAmerican Regent2010-06-30Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousPharma Force, Inc.2010-06-082016-10-13Us
EtomidateInjection, solution2 mg/mLIntravenousAthenex Pharmaceutical Division, Llc.2017-08-01Not applicableUs
EtomidateInjection, solution40 mg/20mLIntravenousAuro Medics Pharma Llc2017-02-24Not applicableUs
EtomidateInjection, solution2 mg/mLIntravenousMylan Institutional2012-02-03Not applicableUs
EtomidateSolution2 mg/mLIntravenousGland Pharma Limited2017-05-20Not applicableUs
EtomidateInjection2 mg/mLIntravenousHeritage2012-09-13Not applicableUs
EtomidateInjection2 mg/mLIntravenousWest Ward Pharmaceutical2016-02-25Not applicableUs
International/Other Brands
Hypnomidate (Janssen)
Categories
UNII
Z22628B598
CAS number
33125-97-2
Weight
Average: 244.289
Monoisotopic: 244.121177766
Chemical Formula
C14H16N2O2
InChI Key
NPUKDXXFDDZOKR-LLVKDONJSA-N
InChI
InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1
IUPAC Name
ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate
SMILES
CCOC(=O)C1=CN=CN1[[email protected]](C)C1=CC=CC=C1

Pharmacology

Indication

Used in the induction of general anesthesia.

Structured Indications
Not Available
Pharmacodynamics

Etomidate is a non-barbiturate hypnotic that acts at the level of the reticular-activating system to produce anesthesia. Etomidate is an imidazole compound that appears to depress CNS function via GABA. Duration of action is intermediate between thiopental and methohexital, and recovery from a single dose is rapid with little residual depression. Like the barbiturates and propofol, etomidate is does not induce analgesia. Etomidate induces unconsciousness within one circulation time. Recovery is rapid as a result of extensive redistribution and rapid metabolism.

Mechanism of action

Etomidate binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged.

TargetActionsOrganism
AGamma-aminobutyric acid receptor subunit alpha-1
agonist
Human
AAlpha-2B adrenergic receptor
agonist
Human
AGABA-A receptor (anion channel)
positive allosteric modulator
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding

76%, primarily to serum albumin.

Metabolism

Hepatic. Metabolized rapidly by ester hydrolysis to inactive metabolites.

Route of elimination

Approximately 75% of the administered dose is excreted in the urine during the first day after injection.

Half life

75 minutes.

Clearance
Not Available
Toxicity

Undesirable side effects of etomidate that may limit its use include pain on injection, myoclonus and adrenocortical suppression lasting 4-6 hours following an induction dose.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with 7-Nitroindazole.Experimental
AcebutololEtomidate may increase the atrioventricular blocking (AV block) activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Etomidate is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Etomidate is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Etomidate is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Etomidate.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Etomidate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Etomidate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Etomidate.Approved, Illicit, Investigational
AlprenololEtomidate may increase the atrioventricular blocking (AV block) activities of Alprenolol.Approved, Withdrawn
AmineptineAmineptine may decrease the antihypertensive activities of Etomidate.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may decrease the antihypertensive activities of Etomidate.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Etomidate.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Etomidate is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Etomidate.Approved, Investigational
ArotinololEtomidate may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ArticaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Etomidate.Approved
AtenololEtomidate may increase the atrioventricular blocking (AV block) activities of Atenolol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Azaperone.Vet Approved
AzelastineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Etomidate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Barbital.Illicit
BefunololEtomidate may increase the atrioventricular blocking (AV block) activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Etomidate is combined with Benzyl alcohol.Approved
BetaxololEtomidate may increase the atrioventricular blocking (AV block) activities of Betaxolol.Approved
BevantololEtomidate may increase the atrioventricular blocking (AV block) activities of Bevantolol.Approved
BisoprololEtomidate may increase the atrioventricular blocking (AV block) activities of Bisoprolol.Approved
BopindololEtomidate may increase the atrioventricular blocking (AV block) activities of Bopindolol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Etomidate.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Etomidate is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Brotizolam.Approved, Withdrawn
BucindololEtomidate may increase the atrioventricular blocking (AV block) activities of Bucindolol.Investigational
BufuralolEtomidate may increase the atrioventricular blocking (AV block) activities of Bufuralol.Experimental, Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Bupivacaine.Approved, Investigational
BupranololEtomidate may increase the atrioventricular blocking (AV block) activities of Bupranolol.Approved
BuprenorphineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Etomidate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Etomidate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Etomidate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Etomidate is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Etomidate.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Etomidate is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etomidate.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Etomidate is combined with Carisoprodol.Approved
CarteololEtomidate may increase the atrioventricular blocking (AV block) activities of Carteolol.Approved
CarvedilolEtomidate may increase the atrioventricular blocking (AV block) activities of Carvedilol.Approved, Investigational
CeliprololEtomidate may increase the atrioventricular blocking (AV block) activities of Celiprolol.Approved, Investigational
CetirizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Etomidate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloroprocaine.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Etomidate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Etomidate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Etomidate is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with clomethiazole.Investigational
ClomipramineClomipramine may decrease the antihypertensive activities of Etomidate.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Etomidate is combined with Clopenthixol.Experimental
CloranololEtomidate may increase the atrioventricular blocking (AV block) activities of Cloranolol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Etomidate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Etomidate is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Etomidate.Approved
CocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Etomidate.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may decrease the antihypertensive activities of Etomidate.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Etomidate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Etomidate.Approved
DesipramineDesipramine may decrease the antihypertensive activities of Etomidate.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may decrease the antihypertensive activities of Etomidate.Approved
DetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dexmedetomidine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Etomidate is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Etomidate.Approved, Illicit, Vet Approved
DibenzepinDibenzepin may decrease the antihypertensive activities of Etomidate.Experimental
Diethyl etherThe risk or severity of adverse effects can be increased when Etomidate is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Etomidate.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Etomidate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Etomidate.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Etomidate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Etomidate is combined with Doramectin.Vet Approved
DosulepinDosulepin may decrease the antihypertensive activities of Etomidate.Approved
DoxepinDoxepin may decrease the antihypertensive activities of Etomidate.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Etomidate is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Drotebanol.Experimental, Illicit
DuloxetineDuloxetine may decrease the antihypertensive activities of Etomidate.Approved
DyclonineThe risk or severity of adverse effects can be increased when Etomidate is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Etomidate is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Etomidate is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Etomidate.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Etomidate is combined with Entacapone.Approved, Investigational
EpanololEtomidate may increase the atrioventricular blocking (AV block) activities of Epanolol.Experimental
EscitalopramThe risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.Approved, Investigational
EsmirtazapineEsmirtazapine may decrease the antihypertensive activities of Etomidate.Investigational
EsmololEtomidate may increase the atrioventricular blocking (AV block) activities of Esmolol.Approved
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Etomidate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Etomidate.Approved
EthanolEtomidate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Etomidate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Etizolam.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etomidate is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Etomidate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Etomidate.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Etomidate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Etomidate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Etomidate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etomidate.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Etomidate is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Etomidate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Etomidate is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Etomidate.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Etomidate is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Etomidate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etomidate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Etomidate is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Hexobarbital.Approved
HydrocodoneEtomidate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Etomidate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Iloperidone.Approved
ImipramineImipramine may decrease the antihypertensive activities of Etomidate.Approved
IndalpineThe risk or severity of adverse effects can be increased when Etomidate is combined with Indalpine.Investigational, Withdrawn
IndenololEtomidate may increase the atrioventricular blocking (AV block) activities of Indenolol.Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Etomidate is combined with Indiplon.Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Etomidate.Approved
IprindoleIprindole may decrease the antihypertensive activities of Etomidate.Experimental
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Etomidate.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Etomidate.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Ketobemidone.Approved
LabetalolEtomidate may increase the atrioventricular blocking (AV block) activities of Labetalol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Etomidate is combined with Lamotrigine.Approved, Investigational
LandiololEtomidate may increase the atrioventricular blocking (AV block) activities of Landiolol.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Etomidate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Etomidate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may decrease the antihypertensive activities of Etomidate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Etomidate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Etomidate.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Etomidate is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Etomidate is combined with Lofentanil.Illicit
LofepramineLofepramine may decrease the antihypertensive activities of Etomidate.Experimental
LoprazolamThe risk or severity of adverse effects can be increased when Etomidate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Etomidate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Etomidate.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Etomidate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Etomidate is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Etomidate is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Etomidate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Etomidate is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Melperone.Approved
MepindololEtomidate may increase the atrioventricular blocking (AV block) activities of Mepindolol.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Etomidate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Etomidate is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Etomidate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Etomidate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Etomidate.Approved
MethotrimeprazineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Etomidate is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Etomidate is combined with Methylphenobarbital.Approved
MetoprololEtomidate may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MetyrosineEtomidate may increase the sedative activities of Metyrosine.Approved
MianserinThe therapeutic efficacy of Etomidate can be decreased when used in combination with Mianserin.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Etomidate.Approved, Illicit
MilnacipranMilnacipran may decrease the antihypertensive activities of Etomidate.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Investigational
MirtazapineMirtazapine may decrease the antihypertensive activities of Etomidate.Approved
MolindoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Etomidate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved, Investigational
NadololEtomidate may increase the atrioventricular blocking (AV block) activities of Nadolol.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Etomidate.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Etomidate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Etomidate.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Etomidate is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may decrease the antihypertensive activities of Etomidate.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Etomidate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Etomidate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Etomidate is combined with Ondansetron.Approved
OpipramolOpipramol may decrease the antihypertensive activities of Etomidate.Investigational
OpiumThe risk or severity of adverse effects can be increased when Etomidate is combined with Opium.Approved, Illicit
OrphenadrineEtomidate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Etomidate is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Etomidate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxethazaine.Investigational
OxprenololEtomidate may increase the atrioventricular blocking (AV block) activities of Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Etomidate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Etomidate.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Etomidate.Approved
ParaldehydeEtomidate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Paroxetine.Approved, Investigational
PenbutololEtomidate may increase the atrioventricular blocking (AV block) activities of Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Etomidate is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Etomidate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Etomidate.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
PerazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Etomidate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Etomidate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Etomidate.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Etomidate is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Etomidate.Approved
PindololEtomidate may increase the atrioventricular blocking (AV block) activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Etomidate is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Etomidate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Etomidate is combined with Pomalidomide.Approved
PractololEtomidate may increase the atrioventricular blocking (AV block) activities of Practolol.Approved
PramipexoleEtomidate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Etomidate.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Etomidate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Etomidate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Etomidate is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Proparacaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Etomidate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Propoxycaine.Approved
PropranololEtomidate may increase the atrioventricular blocking (AV block) activities of Propranolol.Approved, Investigational
ProtriptylineProtriptyline may decrease the antihypertensive activities of Etomidate.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Etomidate is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Etomidate is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Etomidate.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Etomidate.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Etomidate is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Etomidate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Etomidate.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Etomidate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Etomidate is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Romifidine.Vet Approved
RopiniroleEtomidate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Ropivacaine.Approved
RotigotineEtomidate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Etomidate.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Etomidate.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Etomidate is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Etomidate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Etomidate.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
SotalolEtomidate may increase the atrioventricular blocking (AV block) activities of Sotalol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Etomidate is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etomidate.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Etomidate is combined with Sulpiride.Approved
SultoprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Sultopride.Experimental
SuvorexantEtomidate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TalinololEtomidate may increase the atrioventricular blocking (AV block) activities of Talinolol.Investigational
TandospironeThe risk or severity of adverse effects can be increased when Etomidate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Etomidate is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Etomidate.Approved
TertatololEtomidate may increase the atrioventricular blocking (AV block) activities of Tertatolol.Experimental
TetrabenazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Etomidate is combined with Tetrodotoxin.Investigational
ThalidomideEtomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Etomidate is combined with Thiopental.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Etomidate.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Etomidate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiagabine.Approved
TianeptineTianeptine may decrease the antihypertensive activities of Etomidate.Approved
TiaprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tilidine.Experimental
TimololEtomidate may increase the atrioventricular blocking (AV block) activities of Timolol.Approved
TizanidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Etomidate is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Etomidate is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Etomidate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Etomidate is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Etomidate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Etomidate is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Etomidate is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etomidate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Etomidate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine.Approved, Vet Approved
TrimipramineTrimipramine may decrease the antihypertensive activities of Etomidate.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Etomidate is combined with Valproic Acid.Approved, Investigational
VenlafaxineVenlafaxine may decrease the antihypertensive activities of Etomidate.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Etomidate is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Etomidate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Etomidate is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Etomidate is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Etomidate is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Etomidate is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Etomidate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Etomidate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Etomidate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Etomidate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Etomidate is combined with Zolazepam.Vet Approved
ZolpidemEtomidate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Etomidate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Etomidate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Etomidate is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Etomidate.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Douglas E. Raines, "ETOMIDATE ANALOGUES THAT DO NOT INHIBIT ADRENOCORTICAL STEROID SYNTHESIS." U.S. Patent US20130079381, issued March 28, 2013.

US20130079381
General References
Not Available
External Links
Human Metabolome Database
HMDB14437
KEGG Drug
D00548
KEGG Compound
C07522
PubChem Compound
667484
PubChem Substance
46507012
ChemSpider
580864
BindingDB
50125935
ChEBI
4910
ChEMBL
CHEMBL681
Therapeutic Targets Database
DAP000669
PharmGKB
PA164743987
Drugs.com
Drugs.com Drug Page
Wikipedia
Etomidate
ATC Codes
N01AX07 — Etomidate
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3Enrolling by InvitationTreatmentCritical Illness1
3RecruitingTreatmentStrokes1
3WithdrawnNot AvailableHypertensive1
4Active Not RecruitingTreatmentAnaesthesia therapy / Electroconvulsive Therapy1
4CompletedPreventionAdrenocortical Deficiency / Hemodynamics Instability1
4CompletedPreventionInduction of Anaesthesia1
4CompletedTreatmentAirway Control / Anaesthesia therapy / Complications / Intubations1
4CompletedTreatmentCholangiocarcinomas / Choledocholithiasis / Malignant Neoplasm of Pancreas / Pancreatitis1
4CompletedTreatmentConscious Sedation Failure During Procedure1
4CompletedTreatmentCoronary Artery Disease / Mitral Valve Regurgitation1
4CompletedTreatmentCoronary Artery Disease / Valvular Heart Disease1
4CompletedTreatmentIntubation; Difficult1
4CompletedTreatmentSurgery, Cardiac1
4Not Yet RecruitingTreatmentDelirium / Hemodynamics Instability1
4Not Yet RecruitingTreatmentMyoclonus1
4RecruitingTreatmentCardio-respiratory arrest / Respiratory Arrest1
4RecruitingTreatmentDepressive State1
4Unknown StatusTreatmentAnaesthesia therapy / Hemodynamics / Oxidative Stress1
4Unknown StatusTreatmentAnaesthesia therapy / Pregnancy Termination1
4Unknown StatusTreatmentBispectral Index / Etomidate / Induction / Pediatric1
4Unknown StatusTreatmentCongenital Choledochal Cyst / Congenital Hydronephrosis / Fracture Bone1
4Unknown StatusTreatmentCoronary Artery Bypass Surgery1
4Unknown StatusTreatmentHemodynamics / Hysteroscopy / Sedation therapy1
4Unknown StatusTreatmentAdjunct to general anesthesia therapy / Target Controlled Infusion (TCI)1
Not AvailableCompletedNot AvailableNeuromuscular Monitoring1
Not AvailableCompletedBasic ScienceDepressive State1
Not AvailableCompletedPreventionAdrenal Insufficiency1
Not AvailableCompletedTreatmentComplication of Gastrostomy1
Not AvailableCompletedTreatmentSepsis / Traumas1
Not AvailableNot Yet RecruitingTreatmentPostoperative Complications1
Not AvailableRecruitingTreatmentIschemia, Brain / Strokes1
Not AvailableRecruitingTreatmentMajor Depressive Disorder (MDD)1
Not AvailableWithdrawnNot AvailableTraumas1

Pharmacoeconomics

Manufacturers
  • Hospira inc
  • Bedford laboratories div ben venue laboratories inc
  • Parenta pharmaceuticals inc
  • Pharmaforce inc
Packagers
Dosage forms
FormRouteStrength
InjectionIntravenous2 mg/mL
Injection, solutionIntravenous2 mg/mL
Injection, solutionIntravenous20 mg/10mL
Injection, solutionIntravenous40 mg/20mL
SolutionIntravenous2 mg/mL
Prices
Unit descriptionCostUnit
Amidate 2 mg/ml vial1.55USD ml
Amidate 2 mg/ml ampul1.19USD ml
Etomidate 2 mg/ml vial1.18USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)142-142.8Godefroi, E.F. and Van Der Eijcken, C.A.M.; U.S. Patent 3,354,173; November 21, 1967; assigned to Janssen Pharrnaceutica NV (Belgium).
water solubility63.2 mg/LNot Available
logP3.05POMONA (1987)
Predicted Properties
PropertyValueSource
Water Solubility0.477 mg/mLALOGPS
logP2.66ALOGPS
logP2.5ChemAxon
logS-2.7ALOGPS
pKa (Strongest Basic)4.54ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area44.12 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity69.59 m3·mol-1ChemAxon
Polarizability26.43 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9908
Blood Brain Barrier+0.95
Caco-2 permeable+0.6275
P-glycoprotein substrateNon-substrate0.7386
P-glycoprotein inhibitor INon-inhibitor0.8567
P-glycoprotein inhibitor IINon-inhibitor0.8597
Renal organic cation transporterNon-inhibitor0.7918
CYP450 2C9 substrateNon-substrate0.7947
CYP450 2D6 substrateNon-substrate0.9117
CYP450 3A4 substrateNon-substrate0.7671
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.5432
CYP450 3A4 inhibitorInhibitor0.7959
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8357
Ames testNon AMES toxic0.7989
CarcinogenicityNon-carcinogens0.8795
BiodegradationNot ready biodegradable0.5121
Rat acute toxicity2.5459 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9622
hERG inhibition (predictor II)Non-inhibitor0.8553
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbonylimidazoles. These are substituted imidazoles in which the imidazole ring bears a carbonyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Imidazoles
Direct Parent
Carbonylimidazoles
Alternative Parents
N-substituted imidazoles / Benzene and substituted derivatives / Heteroaromatic compounds / Carboxylic acid esters / Monocarboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organonitrogen compounds / Organic oxides
show 1 more
Substituents
Imidazole-4-carbonyl group / Monocyclic benzene moiety / Benzenoid / N-substituted imidazole / Heteroaromatic compound / Carboxylic acid ester / Carboxylic acid derivative / Monocarboxylic acid or derivatives / Azacycle / Organic nitrogen compound
show 7 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
ethyl ester, imidazoles (CHEBI:4910)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Inhibitory extracellular ligand-gated ion channel activity
Specific Function
Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Gene Name
GABRA1
Uniprot ID
P14867
Uniprot Name
Gamma-aminobutyric acid receptor subunit alpha-1
Molecular Weight
51801.395 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Martin LJ, Oh GH, Orser BA: Etomidate targets alpha5 gamma-aminobutyric acid subtype A receptors to regulate synaptic plasticity and memory blockade. Anesthesiology. 2009 Nov;111(5):1025-35. doi: 10.1097/ALN.0b013e3181bbc961. [PubMed:19809285]
  4. Desai R, Ruesch D, Forman SA: Gamma-amino butyric acid type A receptor mutations at beta2N265 alter etomidate efficacy while preserving basal and agonist-dependent activity. Anesthesiology. 2009 Oct;111(4):774-84. doi: 10.1097/ALN.0b013e3181b55fae. [PubMed:19741491]
  5. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Epinephrine binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name
ADRA2B
Uniprot ID
P18089
Uniprot Name
Alpha-2B adrenergic receptor
Molecular Weight
49565.8 Da
References
  1. Creagh O, Torres H, Rodriguez N, Gatica SR: Alpha-2B adrenergic receptor mediated hemodynamic profile of etomidate. P R Health Sci J. 2010 Jun;29(2):91-5. [PubMed:20496522]
  2. Paris A, Philipp M, Tonner PH, Steinfath M, Lohse M, Scholz J, Hein L: Activation of alpha 2B-adrenoceptors mediates the cardiovascular effects of etomidate. Anesthesiology. 2003 Oct;99(4):889-95. [PubMed:14508322]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Has steroid 11-beta-hydroxylase activity. In addition to this activity, the 18 or 19-hydroxylation of steroids and the aromatization of androstendione to estrone have also been ascribed to cytochro...
Gene Name
CYP11B1
Uniprot ID
P15538
Uniprot Name
Cytochrome P450 11B1, mitochondrial
Molecular Weight
57572.44 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid 11-beta-monooxygenase activity
Specific Function
Preferentially catalyzes the conversion of 11-deoxycorticosterone to aldosterone via corticosterone and 18-hydroxycorticosterone.
Gene Name
CYP11B2
Uniprot ID
P19099
Uniprot Name
Cytochrome P450 11B2, mitochondrial
Molecular Weight
57559.62 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic transporter activity
Specific Function
Facilitative glucose transporter. This isoform may be responsible for constitutive or basal glucose uptake. Has a very broad substrate specificity; can transport a wide range of aldoses including b...
Gene Name
SLC2A1
Uniprot ID
P11166
Uniprot Name
Solute carrier family 2, facilitated glucose transporter member 1
Molecular Weight
54083.325 Da
References
  1. Stephenson KN, Croxen RL, El-Barbary A, Fenstermacher JD, Haspel HC: Inhibition of glucose transport and direct interactions with type 1 facilitative glucose transporter (GLUT-1) by etomidate, ketamine, and propofol: a comparison with barbiturates. Biochem Pharmacol. 2000 Sep 1;60(5):651-9. [PubMed:10927023]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:34